The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression. The agency announced the move Friday, following an executive order by President Donald Trump calling for the agency to speed up access to the mind-altering drugs. The move reflects growing popular support for the psychedelics among Trump’s supporters, including combat veterans and followers of the Make America Healthy Again movement. The FDA also greenlighted initial testing of a drug related to ibogaine, a potent psychedelic linked to dangerous heart rhythms.